<DOC>
<DOCNO>EP-0610655</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Medicament containing dexpanthenol for topical application
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P2500	A61K3116	A61P2502	A61K4732	A61K900	A61P1700	A61P3700	A61K4732	A61P4300	A61P1700	A61P3700	A61K3116	A61K900	A61P4300	A61P2500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61K	A61P	A61K	A61K	A61P	A61P	A61K	A61P	A61P	A61P	A61K	A61K	A61P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P25	A61K31	A61P25	A61K47	A61K9	A61P17	A61P37	A61K47	A61P43	A61P17	A61P37	A61K31	A61K9	A61P43	A61P25	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Sterile medicament for topical admin. comprises dexpanthenol (I), polyacrylate carrier (in partially neutralised form with a mol. wt. of 3,000,000-5,000,000), and opt. preservatives and/or chelating agents.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
MANN GERHARD CHEM PHARM FAB
</APPLICANT-NAME>
<APPLICANT-NAME>
DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BELLMANN GUENTHER DR
</INVENTOR-NAME>
<INVENTOR-NAME>
BELLMANN, GUENTHER, DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Sterile pharmaceuticals with a content of dexpanthenol 
for topical use,
characterized in
 that they contain as vehicle 
polyacrylic acid in partially neutralized form with a molcular 

weight between about 3 - 5 million. 
Sterile pharmaceuticals according to Claim 1,
characterized in
 that they contain polyacrylic 
acid with a molecular weight of 4 million. 
Pharmaceuticals according to Claim 1 or 2,
characterized in
 that the polyacrylic acid is 
in the form of alkali metal, in particular sodium, or amine 

salt. 
Pharmaceuticals according to Claim 1 to 3,
characterized in
 that the pH of the polyacrylic 
acid gel is 6.8 plus minus 0.2. 
Pharmaceuticals according to Claim 1 to 4,
characterized in
 that the polyacrylic acid 
gel contains a preservative. 
Pharmaceuticals according to Claim 1 to 5,
characterized in
 that the gel contains a 
chelating agent. 
Pharmaceuticals according to Claim 1 to 6,
characterized in
 that the gel contains EDTA.  
 
Process for the production of sterile pharmaceuticals 
according to Claim 1,
characterized in
 that a polyacrylic acid 
solution is autoclaved, a solution containing dexpanthenol 

and, where appropriate, preservatives and chelating agents is 
sterilized by filtration, the two solutions are combined, and 

the mixture is adjusted with the intended sterile base to pH 
6.8 plus minus 0.2. 
Process according to Claim 8,
characterized in
 that the neutralized mixture 
is rendered free of bubbles by evacuation. 
Process according to Claim 8,
characterized in
 that the entire process is 
carried out under sterile inert gas. 
</CLAIMS>
</TEXT>
</DOC>
